I think all the page 5 financial summary numbers relate to the 130kt production variant. The $1,188/t figure referenced is the 130kt average cost and the at full production is used twice, but then again on the next page to reference 130ktpa.
I think the Maths at that stage when at full 130kt production may be approx:
- $2,550 * 130kt = $331.5m of revenue.
- $154.42m of production costs (130kt @ $1,188)
- $178m of EBITDA (using $2,550/t gets within $1m to the published figure)
- Throwing these numbers, some capex and lower production in the first few years gets values close to the NPV quoted.
The original scoping study at 50kt was $1,950*50+$900*16.6=$112.4 less $38.2m costs and $1.3m of unknown rounding for $73m cashflow. Costs and Capex have gone up significantly but they are now likely to be a lot more accurate for an operation operating in the US.
Also, while the OEM's will obviously try to push down every input cost, $2.55/kg IRA HPMSM HPMSM isn't going to create the same concerns for them as $50-$80/kg Lithium Hydroxide or $35/t cobalt. Synthetic graphite is also in the $8/kg range so manganese would remain a cheaper battery input material.
- Forums
- ASX - By Stock
- E25
- Ann: HPMSM Feasibility Study Delivers Outstanding Economics
E25
element 25 limited
Add to My Watchlist
0.00%
!
22.5¢

Ann: HPMSM Feasibility Study Delivers Outstanding Economics, page-10
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.43M |
Open | High | Low | Value | Volume |
22.5¢ | 22.5¢ | 21.5¢ | $21.94K | 100.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2779 | 21.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 62609 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2779 | 0.215 |
2 | 5119 | 0.210 |
2 | 8107 | 0.205 |
7 | 59405 | 0.200 |
3 | 13077 | 0.195 |
Price($) | Vol. | No. |
---|---|---|
0.225 | 62609 | 2 |
0.230 | 72958 | 1 |
0.235 | 24800 | 2 |
0.240 | 252084 | 2 |
0.245 | 21276 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
E25 (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online